go-v.orgdoi

GALNT14 -rs9679162 Genotypes Predict Post-immunotherapy Side Effect and Survival in Patients with Hepatitis B Virus-related Hepatocellular Carcinoma

Po‐Ting Lin, Wei Teng, Wei-Ting Chen, Yu‐De Chu, Chung‐Wei Su, Yi‐Chung Hsieh, Chen-Chun Lin, Yung-Chang Lin, Chun-Yen Lin, Chau‐Ting Yeh, Shi-Ming Lin · Journal of Cancer · 2026

  • DOI 10.7150/jca.133473
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2026

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2026

Abstract

Introduction: Genomic alterations have been reported to correlate with patients' response to immune checkpoint inhibitor (ICI) therapy in hepatocellular carcinoma (HCC).The present study aimed to examine whether single nucleotide polymorphism (SNP) is associated with ICI treatment-related side effects and progression-free survival (PFS) in HCC patients.Methods: This retrospective study included 96 patients with HBV-related HCC receiving ICI (atezolizumab plus bevazizumab) therapy between 2020 and 2023.Five SNPs derived from a previous genome-wide association study linking to chemotherapy responses in HCC patients were included.Their predictive values for PFS and side effects were examined.Results: After ICI therapy, patients with GALNT14-rs9679162 "GG" genotype (median PFS = 19.7 months, 95% confidence interval [CI]: 12.3-35.7;p = 0.032) had a longer PFS, whereas GALNT14-rs675230, BMP7-rs6025211, WWOX-rs13338697 or WWOX-rs13333314 were not associated with PFS (all p > 0.05).GALNT14-rs9679162 "GG" genotype (odds ratio [OR] = 0.298, 95% CI: 0.096-0.926;p = 0.036) was also associated with a decreased risk of post-treatment high-grade aspartate aminotransferase (AST) elevation.Multivariate analysis showed that GALNT14-rs9679162 "GG" genotype (hazard ratio [HR] = 0.433, 95% CI: 0.212-0.886;p = 0.022) and high initial albumin-bilirubin (ALBI) grade (HR = 2.053, 95% CI: 1.153-3.590;p = 0.014) were independently associated with PFS.Conclusions: Genetic variant of an SNP, GALNT14-rs9679162, predicts post-treatment PFS and side effect in HBV-related HCC patients receiving ICIs therapy.

Open the resolved locator · 10.7150/jca.133473

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 23:20 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v17p1220.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.